Archive: Company News
— Winner of the Australian Global Innovation Linkages Program
— Funding dedicated to advancing regenerative scaffolds for breast reconstruction and large bone defects
— BellaSeno to lead consortium of renowned commercial and academic partners
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that its Australian subsidiary BellaSeno Pty Ltd has been granted AUD 1 million (EUR 625,600) for the development of regenerative scaffolds for breast reconstruction and large bone defects. The grant was provided under the Australian Global Innovation Linkages Program, which is dedicated to help Australian businesses and researchers collaborate with global partners.